Recknor is big on biomarkers for Covid and other L

Recknor is big on biomarkers for Covid and other LL trials. Hopefully they are looking at C-reactive protein (CRP) marker of inflammation in CD16 and CD17, as it appears to predict pretty well who will benefit from lenzilumab (anti-GM-CSF) and tocilizumab (anti-IL-6):

https://finance.yahoo.com/news/humanigen-anno...00765.html

Quote:

---

Exploratory analysis of LIVE-AIR results in patients with CRP<150 mg/L and aged <85 years of age, which represented 74% of patients with an evaluable CRP at baseline, show lenzilumab improved the likelihood of survival without ventilation by more than 3-fold (OR 3.04; 95% CI: 1.68-5.51, nominal p=0.0003) compared with placebo and mortality was improved by more than 2-fold (OR: 2.22; 95%CI: 1.07-4.67, p=0.034).

While the LIVE-AIR results, reported above, suggest an improved treatment outcome for patients treated with lenzilumab with CRP<150 mg/L, other studies of immunotherapies like tocilizumab show a differential benefit in patients with CRP>150 mg/L. A large observational study in Spain showed tocilizumab was associated with decreased risk of death (adjusted hazard ratio 0.34, 95% confidence interval 0.16–0.72, p 0.005) and ICU admission or death (adjusted hazard ratio 0.39, 95% confidence interval 0.19–0.80, p 0.011) among patients with baseline CRP >150 mg/L but not among those with CRP ≤150 mg/L.

---